Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 18.03 0.22% 0.04
PTLA closed up 0.22 percent on Wednesday, July 1, 2020, on 1.6 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Aug 5
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Up Flat
Historical PTLA trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 132.35%
Morning Star Bullish 132.35%
Above Upper BB Strength 132.35%
Upper Bollinger Band Touch Strength 132.35%
20 DMA Support Bullish 156.11%
Narrow Range Bar Range Contraction 154.66%
New Downtrend Bearish 149.72%
Upper Bollinger Band Touch Strength 154.66%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 141.69%
Upper Bollinger Band Touch Strength 141.69%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Clinical Medicine Surgery Inflammation Seattle Genetics Spinal Muscular Atrophy Inflammatory Disorders Thrombosis Astellas Pharma Anticoagulants Factor X Hematologic Disorders Portola Pharmaceuticals Venous Thromboembolism

Is PTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 31.73
52 Week Low 5.31
Average Volume 5,034,801
200-Day Moving Average 18.62
50-Day Moving Average 15.97
20-Day Moving Average 17.95
10-Day Moving Average 17.97
Average True Range 0.11
ADX 65.55
+DI 48.42
-DI 8.92
Chandelier Exit (Long, 3 ATRs ) 17.73
Chandelier Exit (Short, 3 ATRs ) 18.22
Upper Bollinger Band 18.01
Lower Bollinger Band 17.89
Percent B (%b) 1.18
BandWidth 0.68
MACD Line 0.47
MACD Signal Line 0.65
MACD Histogram -0.1787
Fundamentals Value
Market Cap 1.04 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -3.96
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.15
Resistance 3 (R3) 18.15 18.11 18.13
Resistance 2 (R2) 18.11 18.08 18.11 18.12
Resistance 1 (R1) 18.07 18.06 18.09 18.07 18.12
Pivot Point 18.03 18.03 18.04 18.03 18.03
Support 1 (S1) 17.99 18.00 18.01 17.99 17.94
Support 2 (S2) 17.95 17.98 17.95 17.94
Support 3 (S3) 17.91 17.95 17.93
Support 4 (S4) 17.91